22nd Jan 2015 07:32
LONDON (Alliance News) - AstaZeneca PLC said Thursday that the European Medicines Agency has accepted its marketing authorisation application for its gout treatment lesinurad 200 milligram tablets.
Lesinurad is used for the chronic treatment of hyperuricaemia in combination with xanthine oxidase inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted, AstraZeneca said.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca